‘Excessive Pricing’ Inquiry Widens As EC’s First Antitrust Price Probe Targets Aspen Pharma

 
• By Ian Schofield

The litany of complaints against pharmaceutical companies for imposing “excessive” prices on generic drugs is growing after the European Commission decided to pursue Aspen Pharma over price rises imposed on a range of anticancer products it acquired from GSK.

Rules sign
Has Aspen broken EU competition rules through "excessive pricing" strategies?

More from Pricing Debate

More from Market Access